These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. de Jong MD, Veenstra J, Stilianakis NI, Schuurman R, Lange JM, de Boer RJ, Boucher CA. Proc Natl Acad Sci U S A; 1996 May 28; 93(11):5501-6. PubMed ID: 8643604 [Abstract] [Full Text] [Related]
4. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts. Angarano G, Monno L, Appice A, Giannelli A, Romanelli C, Fico C, Pastore G. AIDS; 1994 Jul 28; 8(7):1013-4. PubMed ID: 7524541 [No Abstract] [Full Text] [Related]
5. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC. J Infect Dis; 1995 Jul 28; 172(1):70-8. PubMed ID: 7541064 [Abstract] [Full Text] [Related]
7. Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations. Eastman PS, Urdea M, Besemer D, Stempien M, Kolberg J. J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul 01; 9(3):264-73. PubMed ID: 7540490 [Abstract] [Full Text] [Related]
8. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine. Masquelier B, Pellegrin I, Ruffault A, Ragnaud JM, Morlat P, Michelet C, Doignon F, Biteau N, Fleury HJ. J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr 01; 8(4):330-4. PubMed ID: 7533640 [Abstract] [Full Text] [Related]
9. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction. Richman DD, Guatelli JC, Grimes J, Tsiatis A, Gingeras T. J Infect Dis; 1991 Dec 01; 164(6):1075-81. PubMed ID: 1720152 [Abstract] [Full Text] [Related]
10. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. J Infect Dis; 1997 Jun 01; 175(6):1502-6. PubMed ID: 9180194 [Abstract] [Full Text] [Related]
11. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. García-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W. J Virol; 2004 Jul 01; 78(14):7545-52. PubMed ID: 15220429 [Abstract] [Full Text] [Related]
12. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy. Smith MS, Koerber KL, Pagano JS. J Infect Dis; 1994 Jan 01; 169(1):184-8. PubMed ID: 7506280 [Abstract] [Full Text] [Related]
13. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Aguiniga E, Halpern J, Merigan TC. J Acquir Immune Defic Syndr (1988); 1994 Aug 01; 7(8):832-8. PubMed ID: 7517448 [Abstract] [Full Text] [Related]
14. In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1-infected patients. Wildemann B, Haas J, Ehrhart K, Wagner H, Lynen N, Storch-Hagenlocher B. Neurology; 1993 Dec 01; 43(12):2659-63. PubMed ID: 7504798 [Abstract] [Full Text] [Related]
15. Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains. Sheehy N, Desselberger U. J Gen Virol; 1993 Feb 01; 74 ( Pt 2)():223-8. PubMed ID: 7679140 [Abstract] [Full Text] [Related]
16. Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients. Calderón EJ, Torres Y, Medrano FJ, Luque F, Larder B, Rey C, Sánchez-Quijano A, Lissen E, Leal M. Eur J Clin Microbiol Infect Dis; 1995 Jun 01; 14(6):512-9. PubMed ID: 7588824 [Abstract] [Full Text] [Related]
17. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA, Gupta P, Rasheed S, Coombs R. J Infect Dis; 1994 Apr 01; 169(4):722-9. PubMed ID: 8133086 [Abstract] [Full Text] [Related]
18. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. Gurusinghe AD, Land SA, Birch C, McGavin C, Hooker DJ, Tachedjian G, Doherty R, Deacon NJ. J Med Virol; 1995 Jul 01; 46(3):238-43. PubMed ID: 7561796 [Abstract] [Full Text] [Related]
19. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Mohri H, Singh MK, Ching WT, Ho DD. Proc Natl Acad Sci U S A; 1993 Jan 01; 90(1):25-9. PubMed ID: 7678340 [Abstract] [Full Text] [Related]
20. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Tisdale M, Kemp SD, Parry NR, Larder BA. Proc Natl Acad Sci U S A; 1993 Jun 15; 90(12):5653-6. PubMed ID: 7685907 [Abstract] [Full Text] [Related] Page: [Next] [New Search]